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Therapeutic Options in 
Retinopathy of Prematurity
Simona Delia Nicoară
Abstract
Preterm babies may develop retinopathy of prematurity (ROP) in various stages. 
Most of them regress spontaneously without treatment, and a small proportion 
develops severe ROP that can lead to visual loss if not treated promptly. Less than 
10% of the ROP cases require treatment worldwide. Before 1980, the only treatment 
for ROP was vitreoretinal surgery for retinal detachment in advanced stages of 
the disease. Around this time, cryotherapy started to be used in order to ablate the 
peripheral retina and interrupt the pathogenic chain in ROP, but there were no indi-
cations correlated with the severity of the disease. Few years later, cryotherapy was 
replaced by indirect laser photocoagulation of the nonvascular retina that became 
the golden standard of treatment for ROP. During the last years, efforts have been 
made in order to find therapeutic methods to induce the regression of new vessels 
with minimal side effects. Among these, intravitreal injections of anti-vascular 
endothelial growth factor (VEGF) became increasingly popular in the treatment of 
ROP worldwide. Personal experience in treating aggressive posterior ROP (APROP) 
with laser versus intravitreal anti-VEGF is presented. Intravitreal anti-VEGF proved 
its superiority in treating APROP as compared to laser, with no systemic and/or 
local side effects in our series.
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1. Introduction
All high-risk pregnancies are on the rise, and most of them result in a premature 
birth which is induced either due to maternal factors or fetal factors. Moreover, 
theoretically there could be more instances where retinopathy of prematurity 
(ROP) can develop because there has been a lot of development as well as success 
in management of preterm babies. Progress in neonatal care was associated with 
higher survival rates of low birth weight and low gestational age newborns.
Retinopathy of prematurity (ROP) is an important threat for the vision of the 
premature infants, especially for those born at low postconceptional ages (PCAs) 
and with low birth weights (BWs) [1, 2].
Following progress in neonatal care, the prevalence of ROP is increasing in the 
developing world, justifying the identification of ROP as a leading cause of visual 
impairment in children in the developing world, by the World Health Organization 
(WHO) [1].
In the developed countries, ROP accounts for 4% of childhood blindness, 
whereas in the developing ones, ROP generates 40% of it [1].
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Many preterm babies will develop ROP in various stages. Most of them regress 
spontaneously without treatment, and a small proportion develops severe ROP 
that can lead to visual loss if not treated promptly [3]. ROP is one of the few largely 
preventable causes of visual impairment in children [3–5].
Fortunately, a treatment is available that can significantly reduce the rate of 
unfavorable outcomes [1]. The early detection of ROP and the prompt treatment 
are crucial for the prevention of blindness. Currently, there are two therapeutic 
methods to treat ROP: intravitreal injections with anti-vascular endothelial growth 
factor (VEGF) agents and indirect laser photocoagulation of the nonvascularized 
retina [2].
2. Pathophysiology of ROP
During the first 4 months of gestation, the retina has no blood vessels, and it is 
nourished by the hyaloid vasculature [6].
At 16 weeks, the angioblasts near the hyaloid artery invade the nerve fiber layer, 
and the first retinal vessels appear at the level of the optic nerve head. They grow 
progressively toward the periphery, reaching the ora serrata at 36 weeks in the nasal 
sector and at 40 weeks in the temporal one [6].
The development of the superficial and deep layers of the retinal vasculature 
depends on the delicate balance between the growth factors which are secreted by 
the astrocytes and the microglia: vascular endothelial growth factor (VEGF) and 
insulin growth factor-1 (IGF-1) [6].
During the second half of pregnancy, there is relative intrauterine hypoxia. 
When premature birth occurs, retinal vessels are not completely developed. Altered 
oxygen condition is a risk factor for the development of ROP which is a biphasic 
disease.
The first phase (from the moment of birth to 31- to 32-week postconceptional 
age) is characterized by relative environmental hyperoxia which leads to the arrest 
of the normal retinal development [6].
During the second phase (from 32- to 36-week postconceptional age), the retina 
matures, and its metabolic needs increase. By consequence, it is characterized by 
relative hypoxia and overexpression of VEGF, IGF-1, and oxidative damage with 
subsequent new vessel growth and retinal detachment [6].
The association between ROP and the administration of high doses of oxygen 
was demonstrated for the first time by Patz et al. in 1953 [6].
3. ROP classification
ROP was classified for the first time in 1984 by an international group of experts 
and updated in 2005. In classifying ROP, three criteria are used: zone, stage, and 
presence/absence of “plus” disease [7].
Topographically, the retina is divided into three zones. Zone 1 corresponds to 
a circle centered on the optic disc and with the radius equal to the double distance 
between the optic disc and the fovea. Zone 2 corresponds to a circle centered on 
the optic disc with the radius equal to the distance between the optic disc and ora 
serrata nasally. Zone 3 corresponds to the remaining crescent of the temporal retina 
up to ora serrata [7].
The stage describes the retinal changes at the limit between the vascular and 
nonvascular retina. Stage 1 is defined by a demarcation line, stage 2 by a nonvas-
cular (white) ridge, and stage 3 by a vascular (red) ridge. Stage 4a corresponds to 
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peripheral retinal detachment, stage 4b involves also the detachment of the fovea, 
and stage 5 represents total retinal detachment in an open or closed funnel. “Plus” 
disease refers to the dilation and irregularity of retinal arteries and veins in the 
posterior pole, as compared to a standard photograph [7].
Aggressive posterior ROP (APROP) is a subtype of ROP with a very unpredict-
able and aggressive behavior. It is always located posterior (zone 1 and posterior 
zone 2), with very severe “plus” disease and with flat neovascularization that 
progresses rapidly, without getting through the stages described above [7].
The Early Treatment for ROP (ETROP) study reclassified ROP according to 
the required attitude: type 1, ROP requiring treatment and type 2, ROP requiring 
closely monitoring.
4. Diagnosis and screening for ROP
Fortunately, it is estimated that less than 10% of the ROP cases require treatment 
worldwide. More than 90% regress spontaneously [1].
Various screening criteria apply in different countries/regions. For instance, 
in the USA, the screening criteria updated in 2013 include all infants with BW of 
1500 g or less or GA 30 weeks or less.
Heavier and more mature babies are included in the screening at the discretion 
of the neonatologist, especially if other complications are present: necrotizing 
enterocolitis, intraventricular hemorrhage, sepsis, and bronchopulmonary dys-
plasia. According to our national guidelines, all premature newborns with GA of 
34 weeks or less or with BW 2000 grams or less are included in the ROP screening.
The first screening should be performed at 4–6 weeks after birth or at PCA 
31 weeks whichever is later. When examining a premature infant, one of three 
situations can be identified: mature retina, immature retinal vascularization, or 
ROP. ROP screening can be discontinued if retinal vascularization is present in zone 
3, without previous zone 1 or zone 2 disease; there is no evidence of prethreshold 
disease or worse ROP by 50 weeks PCA; there is regressing ROP in zone 3 without 
abnormal vascular tissue that can reactivate in zone 2 or 3.
ROP screening is made by trained ophthalmologists, using indirect ophthalmos-
copy and scleral indentation in order to have access to the retinal periphery. Pupils 
must be dilated with a mixture of tropicamide 0.5% and phenylephrine 2.5%, and 
the lids are maintained open with a lid speculum throughout the examination.
5. Prevention and risk factors
The most important factor to prevent ROP is preventing premature birth [6].
The STOP-ROP multicenter study evaluated the risk for prethreshold ROP 
development in correlation with the oxygen saturation, and it showed no difference 
between maintaining an oxygen saturation level of 96–99% versus 89–94% [6].
BOOST II study showed a higher survival rate in infants younger than 28 weeks 
GA with 91–95% oxygen saturation levels but with an increased risk of ROP at this 
oxygen rate in other studies [6].
6. Treatment of ROP
Before 1980 the only treatment for ROP was vitreoretinal surgery for retinal 
detachment in advanced stages of the disease. Around this time cryotherapy started 
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to be used in order to ablate the peripheral retina and thus interrupt the pathogenic 
chain in ROP, but there were no guided indications in correlation with the severity 
of the disease [6].
CRYO-ROP elaborated a classification of ROP and defined “threshold” disease in 
which therapy was indicated: 5 contiguous hours or 8 non-contiguous hours of stage 
3 ROP with plus disease in zone 1 or 2 [8].
A subsequent study, ETROP investigated whether treatment performed earlier 
than in threshold disease would further reduce the rate of anatomic unfavorable 
outcomes. Prethreshold disease was defined as type 1 and type 2 ROP. Clinically, 
type 1 ROP includes the following categories: zone 1 ROP of any stage with plus, 
zone 1 stage 3 ROP without plus, and zone 2 stage 2 or 3 disease with plus. In type 2 
ROP, the following situations are included: zone 1 stage 1 or 2 without plus or zone 
2 stage 3 without plus. ETROP recommends treatment in type 1 ROP and monitor-
ing in type 2 ROP. At 6-year follow-up, the study proved 9% unfavorable structural 
outcomes in the early treated eyes, as compared to 15% unfavorable structural 
outcomes in the conventional treatment group. ETROP recommends peripheral 
laser ablation in type 1 ROP and frequent observation in type 2 ROP.
At this point, ablation of the peripheral retina was made by indirect laser photo-
coagulation that had replaced cryotherapy [9].
There are several advantages of laser over cryotherapy: laser requires less general 
anesthesia, it treats easier the posterior ROP, and it is associated with less systemic 
side effects: apnea, bradycardia, and cardiopulmonary arrest requiring resuscita-
tion. However, ocular complications were reported after extensive indirect diode 
laser photocoagulation: vitreous hemorrhage, cataract, intraocular inflammation, 
choroidal effusion, and elevated intraocular pressure [9]. Theoretically, the risk of 
cataract is very low, given the fact that the infrared radiation that we use is absorbed 
deep into the choroid and not in the crystalline lens. Vitreous hemorrhage is rather a 
sign of ROP progression than a complication related to the laser itself.
Parvaresh et al. published the results of transscleral diode laser photocoagula-
tion instead of transpupillary approach and concluded that it is technically easier, 
especially for retinal periphery and with fewer complications at the level of the 
anterior segment such as cataract formation [10].
During the last years, efforts have been made in order to find therapeutic meth-
ods to induce the regression of new vessels with minimal side effects [10].
Given the role of VEGF in angiogenesis, anti-VEGF administered intravitreally 
emerged as a promising tool for the treatment of ROP, alongside its use in ischemic 
retinopathies. Research conducted over the latest two decades proved that VEGF is 
one of the major factors involved in ROP pathogenesis [10].
VEGF inhibition with subsequent suppression of neovascular disease was 
proved by several experimental and clinical studies [10].
Clinical studies showed significantly higher levels of VEGF in the vitreous of 
patients with vasoproliferative ROP [11–13]. Sato et al. analyzed 27 cytokines in the 
vitreous of ROP eyes and found that VEGF was the most strongly correlated with 
vascularly active ROP [11]. This study also identified other factors elevated in ROP: 
fibroblast growth factor (FGF), granulocyte-colony stimulating factor (G-CSF), 
and granulocyte macrophage-colony stimulating factor (GM-CSF). This observa-
tion sustains the participation of an inflammatory response in the complex process 
of ROP development in addition to known vascular growth factors such as VEGF.
Animal ROP models showed the suppression of the vascular disease following 
intravitreal anti-VEGF injection [14, 15].
Nonobe et al. injected bevacizumab in the vitreous of five premature infants and 
showed the marked decrease of aqueous humor concentration of VEGF in four of 
them. Law et al. injected bevacizumab in 13 eyes of seven premature infants prior 
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to laser or vitrectomy, and they noticed the improvement of the visualization of the 
retina with no systemic side effects, suggesting the role of anti-VEGF therapy prior 
these procedures [10].
A retrospective study carried by Lee et al. on 15 premature infants with stage 
3 ROP showed the rapid regression of plus disease with more rapid development 
of normal vessels toward the retinal periphery, with no significant increase in 
systemic or ocular complications, compared with patients treated with laser 
photocoagulation [10].
Considerably concerns remain regarding the safety of anti-VEGF treatment in 
ROP, especially considering the correct dosage, timing of injection, and potential 
local complications such as infection, lens damage, and effect on the development 
of the neurosensory retina. Systemic side effects were not reported yet, but concern 
persists especially regarding the development of the central nervous system.
The Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of 
Prematurity (BEATROP) study concluded that one doze of bevacizumab 0.625 mg 
in 0.025 ml had significantly better results in reducing the recurrence rate in zone 1 
stage 3 ROP as compared to laser: 6 versus 42%, respectively. However, in posterior 
zone 2 ROP, the results were similar with intravitreal bevacizumab and laser. An 
interesting observation was that in some cases treated with intravitreal bevaci-
zumab, late recurrence was noted: 16 ± 4.6 weeks with bevacizumab, as compared 
to 6.2 ± 5.7 weeks with laser. Therefore, follow-up in anti-VEGF-treated eyes should 
be performed for longer periods [10].
Erythropoietin (Epo) is another growth factor that was proved to promote 
angiogenesis in vitro and in animal models. Recombinant Epo (rhEpo) is used to 
treat anemia in premature infants, as it promotes red blood cell formation. Sato 
et al. showed significantly elevated levels of Epo in 40 eyes from 27 premature 
infants with stage 4 ROP [13]. Suk et al. carried out a retrospective study in which 
he investigated the rhEpo treatment and ROP in 265 patients. The study concluded 
that high dose and later starting age for rhEpo treatment are risk factors for ROP 
(the phase of the disease was not taken into account). However, Shah et al. in a 
retrospective study on 85 patients found no correlation between the rhEpo treat-
ment and the incidence and severity of ROP [16].
Research in the field of angiogenesis led to a number of new ways to prevent 
ROP progression: targeting the insulin growth factor (IGF-1) pathway and dietary 
supplementation with omega-3 polyunsaturated fatty acids (PUFAs) [10].
Following preterm birth, serum IGF-1 is substantially reduced due to the inter-
ruption of fetal-maternal interaction. Animal models of ROP proved that IGF-1 is 
essential for vascular growth through interaction with VEGF signaling. Therefore, 
theoretically, supplementation of IGF-1 during phase 1 ROP would normalize 
vascular growth and subsequently prevent abnormal vascular proliferation in phase 
2 ROP [10].
Omega-3 PUFAs protect against pathologic neovascularization in ROP. They 
lack from the diet of premature infants because there is no transfer from the mother 
during the last trimester. Therefore, studies are planned to investigate the potential 
benefit of supplementing omega-3 PUFA intake in premature infants [10].
Currently, laser photocoagulation of the nonvascular retina remains the only 
well-established, gold standard therapy to prevent ROP progression toward blind-
ness. There is clinical and experimental research going on in order to add therapeu-
tic strategies meant to improve the prognosis of this potentially blinding disease.
Despite timely treatment, it is estimated that approximately 16% of patients 
with type 1 ROP develop retinal detachment. The results reported by a large series 
of cases showed that the reattachment rate following pars plana vitrectomy is corre-
lated with the stage of ROP: 82% for stage 4A, 70% for stage 4B, and 43% for stage 
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5 ROP. Scleral buckles can also be used for stage 4A ROP. A small case series showed 
that the association of a scleral buckle to pars plana vitrectomy did not improve the 
reattachment rate as compared cu PPV alone [10].
Because the therapeutic results in stage 5 ROP are extremely poor, the goal is to 
screen and treat type 1 ROP before the occurrence of retinal detachment.
In some circumstances, exudative retinal detachment is present, as a result of 
leakage from the vascular structures. This type of detachment is usually located 
posterior to the ridge, and it is convex in shape. Favorable results were reported in 
some of these cases after intravitreal administration of bevacizumab [10].
7. Personal experience in the treatment of aggressive posterior ROP 
(APROP)
7.1 Background
APROP is a particularly severe form of ROP defined by the following charac-
teristics: posterior location (zone I or posterior zone II), very dilated and tortuous 
vessels, and development of arteriovenous shunts [17]. The evolution of APROP 
toward retinal detachment is very rapid, without the stages described in the “clas-
sic” form of ROP.
Laser treatment of ROP became available in the Ophthalmology Department 
(“Iuliu Hatieganu” University of Medicine and Pharmacy from Cluj-Napoca, 
Romania) in 2006, whereas intravitreal bevacizumab injections started to be used 
in 2009 (Avastin; Genentech Inc., San Francisco, California, USA).
In this study, we aimed to establish the relative effectiveness and safety of intra-
vitreal bevacizumab (IVB) as compared to laser photocoagulation in APROP.
7.2 Method
We analyzed retrospectively all the files of the consecutive infants with APROP 
that we treated either by laser photocoagulation or with IVB between January 1, 
2006 and December 31, 2013 and were followed for at least 60 weeks (for the laser 
group) and 80 weeks (for the IVB group). The overall follow-up ranged between 
60 and 144 weeks from the treatment. The study was in agreement with the dec-
laration of Helsinki (1964), and it has the approval of the ethics committee of our 
university.
Main outcome measures are represented by APROP regression, and the struc-
tural outcome associated either with laser photocoagulation or with IVB.
7.2.1 Medical intervention
In APROP we perform treatment (laser or IVB) within 24 hours from diagnosis. 
Before the intervention, a mixture of tropicamide 0.5% and phenylephrine 2.5% 
was instilled four times, every 15 minutes in order to obtain pupil dilatation. All laser 
treatments were performed under analgesia and sedation in the neonatology unit. Laser 
energy was delivered transpupillary from a portable diode laser having the emission of 
810 nm, through the indirect ophthalmoscope. The lids were maintained open with a 
lid speculum, and the light and laser energy were focalized on the retina with the help 
of a + 28 diopters lens. We started laser photocoagulation of the retina with a power of 
150 mW which we increased gradually up to the obtaining of the desired effect (whitish 
burn on the retina). We did not exceed 300 mW, the exposure time was 200 ms, and the 
spot dimension was 200 microns in all circumstances. We applied between 4000 and 
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6000 burns per eye in 1 or 2 sessions, according to the amount of the nonvascularized 
retina. The first postlaser checkup took place at 6–7 days and continued every 6–7 days, 
until there was evidence of APROP regression. If APROP failed to regress, re-treatment 
was carried out immediately. The frequency of checkups was determined by the clinical 
course of the disease.
We injected bevacizumab intravitreally for APROP according to the following 
guidelines: topical anesthesia with 0.5% proparacaine hydrochloride administered 
three times, every 2 minutes, topical administration of betadine 5%, fixation of the 
lid speculum, and injection of 0.025 ml (0.625 mg) bevacizumab at 1.5–1.75 mm 
from the limbus (in the pars plicata), with a 30G needle, perpendicularly on the 
globe, aiming the center of the eyeball. For the next 3 days, topical tobramycin eye 
drops were instilled five times/day. The first checkup took place the next day (for 
the risk of endophthalmitis) and then 7 days following the injection. The follow-up 
continued every week and then according to the clinical course of the disease.
7.2.2 Follow-up
The infants treated by laser were followed for at least 60 weeks, every month, 
whereas the ones treated with IVB were followed for at least 80 weeks, every 
2 weeks for the first 3 months and then every month. The follow-up was discontin-
ued when full vascularization of the retina was noticed. The exams were performed 
by three ophthalmologists trained in ROP. In the same time, the patients were fol-
lowed by pediatricians for the risk of systemic complications related to intravitreal 
anti-VEGF therapy.
7.2.3 Anatomical outcome
The anatomical outcome was evaluated by indirect ophthalmoscopy. The follow-
ing signs were considered positive outcome: good pupil dilation and the decrease/
disappearance of retinal vessel tortuosity and of the neovascularization. In the IVB 
group, normal development of the retinal vessels toward periphery was noted. The 
aggravation of APROP was defined if “plus disease” and/or neovascularization 
persisted/reappeared, and there were signs of retinal detachment. In these circum-
stances, laser photocoagulation was added if possible.
7.2.4 Statistical analysis
Statistical analysis was performed using Microsoft Excel and IBM SPSS 
(version 23.0).
7.3 Results
Between January 1, 2006 and December 31, 2013, we treated 23 infants with 
APROP. The laser group includes 6 APROP infants and the intravitreal bevacizumab 
(IVB group) and 17 APROP infants. In both groups, the treatment was bilateral.
7.3.1 Evolution following treatment
APROP treated by laser totalized 24 eyes and by bevacizumab, 34 eyes. Among 
the laser-treated eyes, the outcome was favorable in 18 eyes (75%), and within 
the IVB-treated eyes, result was favorable in 29 eyes (85.29%). Chi-square test 
and Fisher exact test prove no statistically significant difference: p = 0.419 and 
p = 0.412, respectively.
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We needed to repeat laser treatment in 10 of the 24 eyes with APROP (41.66%) 
with good outcome in 8 of them. Supplementary laser spots were applied on the 
skipped areas toward the macula.
APROP regressed in 29 eyes (85.29%) from the IVB-treated group and failed to 
regress in five eyes (14.71%). In three of the five eyes, laser photocoagulation was 
carried out, with favorable outcome in all of them. In the remaining two eyes, laser 
treatment could not be performed due to the lack of visualization.
7.3.2 Comparative evolution after treatment between the two groups
The observed differences between the two groups are statistically significant, as 
proved by McNemar’s test (p < 0.001). Global success rate (bilateral or unilateral 
regression) versus unsuccessful treatment was higher for IVB (94, 12% of cases) 
against laser photocoagulation (66, 66%), but no statistically significance higher 
(Chi-square test p = 0.420, Fisher exact test p = 0.462).
After excluding the infants with bad outcome, who came from the same NICU, 
the difference between the two groups regarding regression rate is no longer sig-
nificant: 85.29% in the IVB group and 81.25% in the laser photocoagulation group 
(p > 0.05).
Treatment worked quicker within the IVB group, as compared to the laser 
photocoagulation group.
The bad outcome was identified 1 week after treatment, in all the 16 eyes within 
this series (11 from the laser photocoagulation group and 5 from the IVB group). We 
had no late recurrence in this series.
7.4 Discussion
7.4.1 Indirect diode laser photocoagulation for APROP
Laser photocoagulation of the retina is the gold standard in the treatment of 
ROP, and it proved its efficacy in more than 90% of ROP cases [18]. On the other 
hand, laser destroys the retina, and complications were cited in relation to it: 
cornea, iris and lens burns, hyphema, uveitis, retinal hemorrhages, and choroidal 
ruptures [19]. In our series, we report two cases of mild anterior uveitis following 
laser photocoagulation for APROP, with prompt resolution following mydriatic and 
anti-inflammatory eye drops.
Laser photocoagulation does not address the underlying cause of the disease 
[18]. Zone 1 APROP is known to have worse prognosis following laser photocoagu-
lation, as compared to the classical form of the disease [20].
Because of the lack of landmarks in APROP, laser photocoagulation of the retina 
toward the posterior pole is difficult, and sometimes untreated areas of the avascu-
lar retina remain as a source of VEGF explaining the progression of the disease. By 
consequence, one single session of laser treatment is often insufficient in APROP.
Within the laser photocoagulation group, APROP final failure rate was 45.83%, 
represented by 11 eyes from 7 infants (four, bilaterally and three, unilaterally). 
From these seven cases, five came from the same neonatal unit and totalize eight 
eyes with bad outcome (three, bilaterally and two, unilaterally). This observation 
can lead us to the supposition that the inadequate neonatal care and oxygen admin-
istration might be at the origin of the severity and unresponsiveness to the laser 
treatment in these cases.
If we exclude these eight eyes from our analysis, the success rate following laser 
photocoagulation for APROP becomes 81.25% (in 13 of the remaining 16 cases, 
APROP could be stopped by laser treatment).
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7.4.2 IVB for APROP in our series
APROP regression rate following IVB was 85.29% in our series (29 of the 34 
eyes). We added laser photocoagulation in all the five eyes with lack of regression 
following IVB, with good outcome in three of them. The two eyes with final poor 
outcome belonged to different infants.
We did not identify any local complication subsequent to IVB in our group. No 
late reactivation of the disease was present.
7.4.3 IVB versus laser photocoagulation in the treatment of APROP
The main reason that determined us to replace laser photocoagulation with IVB 
in APROP was the high failure rate in this form of ROP, following laser treatment, 
in our practice, which is in agreement with data in the literature (45.83%) [21]. 
Besides, there are other disadvantages of laser treatment for APROP: the need to 
apply many laser spots during long and laborious sessions and the need to repeat 
laser because often at the moment of treatment there are no well-defined land-
marks between the vascularized and the nonvascularized retina (typical feature 
of APROP). Often pupils do not dilate well in these severe cases, and vitreous 
hemorrhage can be associated, making laser treatment inadequate. The general 
status of the infant is often severe in APROP cases, making laser treatment risky for 
the patient’s life. Finally, IVB does not destroy the retina as opposed to laser which 
ablates the nonvascularized retina in order to keep alive its vascular part. [21].
APROP regression rate was significantly better following IVB as compared with 
laser photocoagulation in our series. However, when we remove from the laser 
photocoagulation group, the infants with bad outcome, who came from the same 
NICU, the difference is no longer significant.
Another major advantage of IVB over laser is the continuation of retinal vas-
cularization following treatment up to the periphery [20]. This observation was 
verified in our series. Anti-VEGF and laser act by different mechanisms in stopping 
the progression of ROP toward retinal detachment. Whereas laser photocoagula-
tion destroys the source of VEGF (ischemic retina), anti-VEGF annihilates also the 
VEGF already present in the vitreous. This explains the quicker response and higher 
efficacy of IVB as compared to laser in APROP.
According to our experience, all bad outcomes were identified 1 week after 
treatment. Therefore, we consider them as unresponsiveness to treatment, not late 
recurrences [21].
7.4.4 Asymmetric response to treatment
We identified asymmetric response to treatment in six cases: three from the 
laser group and three from the IVB group. The possible explanation of this outcome 
might be the unequal development of the eyes which also explains the rare situation 
of unilateral ROP.
7.4.5 Safety issues related to anti-VEGF therapy
The main issue related to IVB treatment is its safety. There is proof that follow-
ing IVB injections the serum VEGF levels decrease and anti-VEGF was found in the 
systemic circulation [21]. It is known that in ROP the blood-retinal barrier is broken 
down, allowing the exit of anti-VEGF in the systemic circulation, while the infant is 
still during the process of organogenesis. Concern comes from the fact that VEGF is 
necessary for the development of the lungs, brain, kidneys, and skeleton. VEGF also 
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acts as a neural survivor factor inside the eye, and its suppression might prevent the 
development of neural components in the retina [21].
7.4.6 Comparison between laser and IVB in the treatment of ROP
The advantages of IVB over laser photocoagulation in the treatment of ROP 
are related to its simplicity; short duration; lack of retinal destruction, conduct-
ing under topical anesthesia; lower price; and possibility to be performed in the 
eyes with small pupils and hazy media and in infants with poor general condition 
in which laser treatment under general anesthesia would be risky [21]. As proved 
by our series, IVB allows further development of retinal normal vasculariza-
tion up to periphery, as opposed to laser. However, IVB is not risk free as far as 
local complications are considered. Lens injury, intraocular hemorrhage, retinal 
detachment, and endophthalmitis are possible, but they were not reported in the 
literature so far.
According to our experience, the most important advantage of IVB as compared 
to laser treatment is the better outcome in APROP, as published by other authors 
[21]. In this context, IVB represents our first therapeutic indication for APROP, 
even if the systemic safety issues were not fully addressed [21].
In a study that compared laser with bevacizumab in ROP and published in 2015, 
similar results were reported in the two groups, but it included all ROP cases, not 
just the severe ones (APROP) [22].
Other authors found higher recurrence rate of ROP following IVB as compared 
to laser, but within the laser group, macular ectopia had a higher incidence [23]. 
This observation is in agreement with our study that identified macular ectopia 
only in one case from the laser treated group.
In a previously published study, we showed that in the IVB-treated eyes, the 
retinal vascularization continued up to the periphery, unlike with laser [24].
Another observation of this comparative study is that the response to IVB was 
quicker than following laser. The explanation is represented by the fact that anti-
VEGF suppresses not only the VEGF in the retina (such as laser does) but also the 
VEGF which is already released in the vitreous.
8. Conclusion
8.1 Personal experience
Intravitreal bevacizumab has emerged as a very useful tool in the treatment of 
ROP. We found a statistically significant higher APROP regression rate after IVB, 
as compared to laser photocoagulation in our series. IVB is much shorter, easier, 
accessible, and less expensive than laser photocoagulation. We could perform IVB 
in the eyes with small pupils and hazy media. By consequence, bevacizumab given 
intravitreally replaced laser in APROP, becoming the standard of care in this severe 
form of ROP, in our practice.
8.2 General
Progress in neonatal care was associated with higher survival rates of low birth 
weight and low gestational age newborns.
ROP is a biphasic disease: the first phase (from the moment of birth to 
31–32 weeks postconceptional age) is called hyperoxic and it leads to the arrest 
of the normal retinal development, and the second phase (from 32- to 36-week 
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postconceptional age) is called hypoxic with overexpression of VEGF, IGF-1, and 
oxidative damage with subsequent new vessel growth and retinal detachment.
The Early Treatment for ROP study (ETROP) reclassified ROP according to 
the required attitude: type 1, ROP requiring treatment and type 2, ROP requiring 
closely monitoring. APROP is a very severe type 1 ROP characterized by rapid 
evolution toward retinal detachment if not addressed accordingly.
ROP screening should be made by trained ophthalmologists and started at 
4–6 weeks after birth or at PCA 31 weeks whichever is later and continued up to the 
complete vascularization of the retina.
The most important factor to prevent ROP is preventing premature birth.
The gold standard for the treatment of ROP is indirect laser photocoagula-
tion of the nonvascularized retina. Clinical studies conducted during the last 
years proved the superior efficacy of IVB over laser in APROP as well as its other 
advantages.
Research in the field of angiogenesis led to a number of new ways to prevent 
ROP progression: targeting the insulin growth factor (IGF-1) pathway and dietary 
supplementation with omega-3 polyunsaturated fatty acids (PUFA).
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